Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor

Amy C. Porter, John-Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Petra Carter, Frank P. Bymaster, Andrea Baker Leese and Christian C. Felder
Journal of Pharmacology and Experimental Therapeutics June 2002, 301 (3) 1020-1024; DOI: https://doi.org/10.1124/jpet.301.3.1020
Amy C. Porter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John-Michael Sauer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Knierman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald W. Becker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Berna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingqi Bao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George G. Nomikos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petra Carter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank P. Bymaster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Baker Leese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian C. Felder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The first endocannabinoid, anandamide, was discovered in 1992. Since then, two other endocannabinoid agonists have been identified, 2-arachidonyl glycerol and, more recently, noladin ether. Here, we report the identification and pharmacological characterization of a novel endocannabinoid, virodhamine, with antagonist properties at the CB1 cannabinoid receptor. Virodhamine is arachidonic acid and ethanolamine joined by an ester linkage. Concentrations of virodhamine measured by liquid chromatography atmospheric pressure chemical ionization-tandem mass spectrometry in rat brain and human hippocampus were similar to anandamide. In peripheral tissues that express the CB2 cannabinoid receptor, virodhamine concentrations were 2- to 9-fold higher than anandamide. In contrast to previously described endocannabinoids, virodhamine was a partial agonist with in vivo antagonist activity at the CB1 receptor. However, at the CB2 receptor, virodhamine acted as a full agonist. Transport of [14C]anandamide by RBL-2H3 cells was inhibited by virodhamine. Virodhamine produced hypothermia in the mouse and acted as an antagonist in the presence of anandamide both in vivo and in vitro. As a potential endogenous antagonist at the CB1 receptor, virodhamine adds a new form of regulation to the endocannabinoid system.

Footnotes

  • Abbreviations:
    Anandamide
    N-arachidonyl ethanolamide
    2-AG
    2-arachidonoyl glycerol
    LC
    liquid chromatography
    APCI-MS-MS
    atmospheric pressure chemical ionization-tandem mass spectrometry
    DMSO
    dimethyl sulfoxide
    [35S]GTPγS
    guanosine 5′-O-(3-[35S]thio)triphosphate
    methanandamide
    R(+)-arachidonyl-1′-hydroxy-2′-propylamide
    AM404
    N-(4-hydroxyphenyl)arachidonylamide
    WIN 55,212-2
    R-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone
    • Received December 19, 2001.
    • Accepted February 18, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 301 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 301, Issue 3
1 Jun 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor

Amy C. Porter, John-Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Petra Carter, Frank P. Bymaster, Andrea Baker Leese and Christian C. Felder
Journal of Pharmacology and Experimental Therapeutics June 1, 2002, 301 (3) 1020-1024; DOI: https://doi.org/10.1124/jpet.301.3.1020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor

Amy C. Porter, John-Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Petra Carter, Frank P. Bymaster, Andrea Baker Leese and Christian C. Felder
Journal of Pharmacology and Experimental Therapeutics June 1, 2002, 301 (3) 1020-1024; DOI: https://doi.org/10.1124/jpet.301.3.1020
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Substituted tryptamine activity at 5-HT receptors & SERT
  • In Vivo SRI-32743 Attenuates Tat Effects on Extracellular DA
  • Kv7 Opener Attenuates Seizures and Cognitive Deficit
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics